MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD

NCT ID: NCT05979844

Last Updated: 2025-12-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-06
• Study Completion Date: 2025-11-14

Brief Summary

The goal of this pilot trial is to examine the preliminary effectiveness of MDMA-facilitated bCBCT for improving chronic PTSD and relationship functioning in a sample of veterans and their intimate partners seeking care within the VA San Diego Healthcare System.

Detailed Description

The pilot study is a single site, open-label study assessing the preliminary effectiveness, safety, and acceptability of MDMA-assisted therapy in combination with brief Cognitive Behavioral Conjoint Therapy in a sample of 8 veterans diagnosed with PTSD and their intimate partners (N = 16) within the Veterans Affairs San Diego Healthcare System (VASDHS). Therapy teams will deliver the 8 session bCBCT intervention combined with two full-day MDMA sessions for the Veteran diagnosed with PTSD. The veteran with PTSD will be given 80 mg of MDMA HCl with a 40 mg MDMA HCl supplemental dose in the first session and 100 mg of MDMA HCl with a supplemental dose of 40 mg MDMA HCl in the second. The intimate partner will be present for the MDMA sessions (unless they decline or it is clinically contraindicated) but will not receive MDMA. The couples will complete one preparatory session and at least two Emotion Focused Integrative sessions (five max). The PTSD+ veteran will receive telephone check-in calls every other business day for one week following each MDMA session. The first MDMA session occurs in the morning the business day after the preparatory session and the second MDMA session occurs in the morning within 5 business days after bCBCT Session 7. The Emotion-Focused Integrative Sessions take place the morning after each MDMA session. Outcomes examining PTSD symptom severity and relationship functioning will be evaluated for preliminary effectiveness. The study's screening, enrollment, and baseline phase lasts from pre-screen to baseline (approximately 12 weeks, +/- 2 weeks). The treatment period lasts from bCBCT Session 1 to bCBCT Session 8 (7 weeks -13 weeks). The follow-up period lasts from the post-treatment assessment to study termination (24 weeks +/- 15 days).

Conditions

PTSD; Relational Problems

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Non-medicine sessions of bCBCT + Medicine Sessions with 3,4-methylenedioxymethamphetamine (MDMA)

bCBCT Non-medicine sessions: 8 sessions

MDMA Medicine sessions:

Initial Dose 1: 80 mg MDMA HCl (~68 mg MDMA) Supplementary Dose 1: 40 mg MDMA HCl (~34 mg MDMA) Initial Dose 2: 100 mg MDMA HCl (~84 mg MDMA) Supplementary Dose 2: 40 mg MDMA HCl (~34 mg MDMA)

Group Type: EXPERIMENTAL

3,4-methylenedioxymethamphetamine (MDMA)

Intervention Type: DRUG

2 MDMA sessions; PTSD+ Veteran partner only

Brief Cognitive Behavioral Conjoint Therapy (bCBCT)

Intervention Type: BEHAVIORAL

8 bCBCT sessions; Both partners

Interventions

3,4-methylenedioxymethamphetamine (MDMA)

2 MDMA sessions; PTSD+ Veteran partner only

Intervention Type: DRUG

Brief Cognitive Behavioral Conjoint Therapy (bCBCT)

8 bCBCT sessions; Both partners

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

1. Be a veteran (age 18 years or older) who meets criteria for PTSD on the CAPS-5 or be an intimate partner (age 18 or older) of a veteran meeting the criteria for PTSD who is willing to participate in the intervention and who does not meet criteria for PTSD on the PCL-5 (i.e., must score a 30 or lower).

2. Be in a committed relationship together of at least 12 months, and be cohabiting.

3. Be fluent in speaking and reading English.

4. Are willing to commit to medication dosing, therapy sessions, follow-up sessions, completing evaluation instruments, and all necessary telephone contact.

5. Be able to swallow pills. (PTSD+ veteran only)

6. Agree to have study visits recorded, including Experimental MDMA Sessions, and be aware that Independent Rater assessments for bCBCT sessions will occur.

7. Provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable. (PTSD+ veteran only)

8. Agree to inform the investigators within 48 hours of any new medical conditions or procedures.

9. If able to become pregnant (i.e., assigned female at birth, fertile, following menarche and until becoming post-menopausal unless permanently sterile), must have a highly sensitive negative pregnancy test at study entry and prior to each Experimental MDMA Session, and must agree to use adequate birth control through 10 days after the last Experimental MDMA Session. Adequate birth control methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e., condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). (PTSD+ veteran only)

10. Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Experimental MDMA Sessions. (PTSD+ veteran only)

11. Not enroll in any other interventional clinical trials during the duration of the study, and commit to medication dosing, therapy, and study procedures.

12. Both partners agree to not begin a new form of mental healthcare during the screening or treatment phases of the trial, without first discussing with the PI in consultation with the study physician.

1. It is acceptable for participants to continue ongoing non-PTSD focused or non-couple-based mental healthcare, if it is not increased in frequency or specifically excluded by the study protocol.

2. All ongoing therapies should be documented by the site and discussed with the study physician prior to enrollment to avoid confounding treatment effects. In some instances, the study physician may request that the participant delay enrollment until their planned course of therapy is complete, and an integration period has elapsed.

3. Participants may continue with PTSD focused and/or couple-based mental health care during the screening period prior to Baseline and following treatment period prior to study termination if they have approval from the study PI and their study provider (as applicable).

Medical History - PTSD+ veteran only unless otherwise noted

13. At Pre-Screening, have at least moderate PTSD symptoms in the last month based on PCL-5 total score of 40 or greater (index).

14. May have well-controlled hypertension that has been successfully treated with anti- hypertensive medicines if they pass additional screening to rule out underlying cardiovascular disease.

15. May have asymptomatic Hepatitis C virus (HCV) that has previously undergone evaluation and treatment as needed.

16. At Screening, have at least moderate PTSD per CAPS-5 and symptoms in the last month constituting a CAPS-5 Total Severity Score of 28 or greater (index).

17. May have alcohol or substance use disorder if participant is not in withdrawal or requiring detox. Participants/couples must have a plan, agreed upon by investigator, therapy team, and study physician, to reduce use of alcohol or other substances and to manage symptoms without self-medicating. Enrollment will require that, in the judgment of the investigator, therapy team, and study physician, the plan for decreasing substance use is realistic and has a good chance of succeeding in order to prevent substance use from impacting the safety or effectiveness of the investigational treatment. (Both partners)

18. May have a history of or current Diabetes Mellitus (Type 2) if additional screening measures rule out underlying cardiovascular disease, if the condition is judged to be stable on effective management, and with approval by the study physician.

19. May have hypothyroidism if taking adequate and stable thyroid replacement medication.

20. May have a history of, or current, glaucoma if approval for study participation is received from an ophthalmologist.

Exclusion Criteria

1. Are not able to give adequate informed consent.

2. Are currently engaged in compensation and pension (C&P) litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders.

3. Are likely, in the investigator's opinion and via assessment period, to be re- exposed to their index trauma or other significant trauma, lack social support, or lack a stable living situation

4. Have used Ecstasy (material represented as containing MDMA) more than 10 times within the last 10 years or at least once within 6 months of the first Experimental MDMA Session. (PTSD+ veteran only)

5. Have any current problem which, in the opinion of the investigator or study physician, might interfere with participation due to it impacting the patient's safety and/or ability to participate in the protocol

6. Have hypersensitivity to any ingredient of the Investigational Medicinal Product (IMP). (PTSD+ veteran only)

Psychiatric History - both members of dyad unless otherwise noted

7. Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment. (PTSD+ veteran only)

8. Have a history of or a current primary psychotic disorder assessed via the DIAMOND and clinical interview

9. Have a history of or a current Bipolar I disorder, Bipolar 2 disorder, or manic episode assessed via the DIAMOND and clinical interview (PTSD+ veteran only)

10. Have a current eating disorder with active purging assessed via DIAMOND and clinical interview. (PTSD+ veteran only)

11. Have current major depressive disorder with psychotic features assessed via DIAMOND

12. Have current panic disorder assessed via DIAMOND (PTSD+ veteran only)

13. Have a current alcohol or substance use disorder other than caffeine or nicotine that the investigators, therapy team, and/or study physician judge to be a safety concern for enrollment in the study or that could interfere with the therapeutic process or with other aspects of study participation. Any participant who is not able to agree or adhere to a plan to reduce use and manage symptoms will not be enrolled

14. Present with current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS (scores of four or greater), and clinical judgment of the investigator; however, history of suicide attempts is not an exclusion. Any participant who is likely to require hospitalization related to suicidal ideation and behavior, in the judgment of the investigator, will not be enrolled. Any participant presenting with the following on the pre-screen C-SSRS will be excluded:

1. Suicidal ideation score of 4 or greater within the last 6 months of the assessment at a frequency of once a week or more

2. Any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment. Participants with non-suicidal self- injurious behavior may be included if approved by the study physician

15. Report intimate partner violence or severe relationship aggression, as defined by meeting either of the following criteria, that that the investigators and/or therapy team judge to be a safety concern for enrollment in the study or that could interfere with the therapeutic process or with other aspects of study participation:

1. A score of ≥7 on the Extended - Hurt, Insult, Threaten, Scream (E-HITS) screening tool

2. A score of "severe" on the Psychological Aggression scale of the Revised Conflict Tactics Inventory (CTS-2)

16. Would present a serious risk to others as established through clinical interview and if necessary, discussion with treating psychiatrist

17. Require ongoing concomitant therapy with a psychiatric medication other than the exceptions described in protocol section on Concomitant Therapy. (PTSD+ veteran)

Medical History - PTSD+ veteran only

18. Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, or aneurysm. Participants with other mild, stable chronic medical problems may be enrolled if the study physician and PI agree the condition would not significantly increase the risk of MDMA administration or be likely to produce significant symptoms during the study that could interfere with study participation or be confused with side effects of the IMP. Examples of stable medical conditions that could be allowed include, but are not limited to Diabetes Mellitus (Type 2), Human Immunodeficiency Virus (HIV) infection, Gastroesophageal Reflux Disease (GERD), etc. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism would require exclusion.

19. Have a diagnosis of uncontrolled hypertension defined by the American Heart Association as repeated readings of ≥ 140 millimeters of Mercury [mmHg] systolic or ≥ 90 mmHg diastolic

20. Have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease

21. Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation

22. Have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening. Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled only if they have been successfully treated with ablation and have not had recurrent arrhythmia for at least one year off all antiarrhythmic drugs and confirmed by a cardiologist

23. Have a marked Baseline prolongation of QT/QTc interval. For purposes of eligibility, this is defined as repeated demonstration of a QT interval corrected using Fridericia's formula [QTcF] >450 milliseconds [ms]

24. Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)

25. Require use of concomitant medications that prolong the QT/QTc interval during Sessions. Refer to protocol section on Concomitant Medications

26. Have symptomatic liver disease or have significant liver enzyme elevations

27. Have history of hyponatremia or hyperthermia

28. Weigh less than 48 kilograms (kg)

29. Are pregnant or nursing or are able to become pregnant and are not able/willing to practice an effective means of birth control

30. Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment

31. Have any preexisting conditions that can affect renal functioning

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Healing Breakthrough

UNKNOWN

Sponsor Role: collaborator

Lykos Therapeutics

INDUSTRY

Sponsor Role: collaborator

San Diego Veterans Healthcare System

FED

Sponsor Role: collaborator

Dr. Leslie Morland

FED

Sponsor Role: lead

Responsible Party

Dr. Leslie Morland

Dr. Leslie Morland

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Leslie Morland

Role: PRINCIPAL_INVESTIGATOR

San Diego Veterans Healthcare System

Locations

VA San Diego Healthcare System, San Diego, CA

San Diego, California, United States

Countries

United States

References

Morland LA, Perivoliotis D, Wachsman TR, Alam A, Knopp K, Khalifian C, Ramanathan D, Chargin BE, Bismark AW, Glynn S, Stauffer C, Wagner AC. MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study. Contemp Clin Trials Commun. 2024 May 24;40:101314. doi: 10.1016/j.conctc.2024.101314. eCollection 2024 Aug.

Reference Type: DERIVED

PMID: 38994348 (View on PubMed)

Other Identifiers

IVAPT2

Identifier Type: -

Identifier Source: org_study_id